• Publications
  • Influence
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
TLDR
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
TLDR
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
Risk factors for doxorubicin-induced congestive heart failure.
TLDR
There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
TLDR
GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma.
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
TLDR
The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
TLDR
The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease.
Hypersensitivity reactions from taxol.
TLDR
Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur.
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
TLDR
It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression.
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
TLDR
A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms.
...
...